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Background: Methylmalonate semialdehyde dehydrogenase (MMSDH) deficiency is a rare autosomal recessive
disorder with varied metabolite abnormalities, including accumulation of 3-hydroxyisobutyric, 3-hydroxypropionic,
3-aminoisobutyric and methylmalonic acids, as well as β-alanine. Existing reports describe a highly variable clinical
and biochemical phenotype, which can make diagnosis a challenge. To date, only three reported cases have been
confirmed at the molecular level, through identification of homozygous mutations in ALDH6A1, the gene encoding
MMSDH. Confirmation by enzyme assay has until now not been possible, due to the extreme instability of the
enzyme substrate.
Methods and results: We report a child with severe developmental delays, abnormal myelination on brain MRI,
and transient/variable elevations in lactate, methylmalonic acid, 3-hydroxyisobutyric and 3-aminoisobutyric acids.
Compound heterozygous mutations were identified by exome sequencing and confirmed by Sanger sequencing
within exon 6 (c.514 T > C; p. Tyr172His) and exon 12 (c.1603C > T; p. Arg535Cys) of ALDH6A1. The resulting amino
acid changes, both occurring in residues conserved among mammals, are predicted to be damaging at the protein
level. Subsequent MMSDH enzyme assay demonstrated reduced activity in patient fibroblasts, measuring 2.5
standard deviations below the mean.
Conclusions: We present the fourth reported case of MMSDH deficiency with confirmation at the molecular level,
and expand on what is already an extremely variable clinical and biochemical phenotype. Furthermore, this is the
first report to demonstrate a corresponding reduction in MMSDH enzyme activity. This report illustrates the
emerging utilization of whole exome sequencing and variant data filtering using clinical data as an early tool in the
diagnosis of rare and variable conditions.
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Methylmalonate semialdehyde dehydrogenase (MMSDH)
is involved in the catabolic breakdown of both valine and
thymine (MIM#603178). Metabolism of valine produces
the intermediate (S)-3-hydroxyisobutyric acid (HIBA),
which is oxidized to (S)-methylmalonic semialdehyde
(MMSA) by 3-hydroxyisobutyrate dehydrogenase. Thy-
mine metabolism generates (R)-aminoisobutyric acid
(AIBA), which is then deaminated to (R)-methylmalonic
semialdehyde. These two enantiomers of MMSA are sub-
strates for MMSDH, which catalyzes their oxidative de-
carboxylation to propionyl-CoA (Figure 1). Very few
case reports have described individuals with MMSDH
deficiency, and all have been in the context of elevated
urine levels of 3-hydroxyisobutyric acid, among other
metabolic abnormalities. The initial report by Pollitt
et al. [1] describes an asymptomatic child ascertained
due to high methionine levels on newborn screening,
who was found to have 3-hydroxyisobutyric aciduria,
and ultimately shown to carry a homozygous missense
mutation (c.1336G >A) in ALDH6A1, the gene encoding
MMSDH [2]. A recent report described two unrelated
children with 3-hydroxyisobutyric aciduria and different,
novel homozygous missense mutations in ALDH6A1 [3].
Neither report could demonstrate a reduction in
MMSDH enzyme activity, given the unstable behaviourFigure 1 Valine and thymine catabolism, resulting in the oxidative de
propionyl-CoA by methylmalonate semialdehyde dehydrogenase. HIBof methylmalonate semialdehyde in enzyme assays. As
such, the discovery of deleterious mutations in ALDH6A1
has until recently served as the only means of diagnosing
MMSDH dysfunction.
In this report, we describe a young female child with
severe developmental delays, abnormal brain MRI and
transient elevations in methylmalonic acid (MMA), in
addition to raised levels of 3-hydroxyisobutyrate and
plasma lactate. Exome sequencing revealed novel com-
pound heterozygous missense mutations in ALDH6A1,
with subsequent studies in fibroblasts demonstrating
reduced MMSDH enzyme activity. This is the fourth case
of a child with deficiency of MMSDH due to mutations
in ALDH6A1, and the first such case to concurrently
demonstrate a deficiency at the enzyme level. This report
expands our understanding of the biochemical and clinical
aspects of this very rare condition, and highlights that it
may in fact be significantly under-diagnosed, given that
many of the biochemical abnormalities initially observed
in our patient had normalized by the age of 18 months.
Patient and methods
Institutional research ethics board approval (Children’s
Hospital of Eastern Ontario) was obtained prior to this
study. Parents of the patient provided informed consent
for exome sequencing as well as permission to publishcarboxylation of methylmalonic semialdehyde (MMSA) into
A: 3-hydroxyisobutyric acid; AIBA: 3-aminoisobutyric acid.
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report.
Clinical description
The patient (AB), now 36 months of age, was initially re-
ferred at 7 months for developmental delays, dysmorphic
features, and slightly raised urine and plasma me-
thylmalonic acid. She was born at 40 + 5 weeks gestation
to non-consanguineous parents following an uneventful
pregnancy and delivery. Birth weight was 3657 g (75th
percentile). She was found to be hypotonic and have
visual fixation and tracking difficulties at 3 months of
age, thereby initiating clinical investigation. By 19 months
of age she had made slow progress, but continued to
show global developmental delay without regression. She
could sit with assistance, but was unable to crawl or pull
to stand. Vocalizations consisted of monosyllabic noises.
She has never had a seizure-like episode. Family history
is significant only for a paternal cousin with congenital
deafness.
Initial physical examination revealed normal growth
parameters (head circumference 50th percentile, length
75th percentile, weight 90-95th percentile). However,
interval growth in head circumference has not ad-
equately progressed, and at the time of this report was
at the 10th percentile. Her face had a square shape, with
slight frontal bossing, a tall forehead, and sparse hair
temporally. Ocular findings included bilateral epicanthic
folds, mild hypertelorism, and bilateral mottled retinal
pigmented epithelium. The nose was short and ante-
verted, with a broad, flat base, and a short philtrum. Her
mouth was tented and she had a high-arched palate.
Halluces were broad bilaterally, and a single palmar
crease was noted on the right palm. Axial tone was
markedly decreased, with fluctuating peripheral tone.
Deep tendon reflexes were brisk, but there was no ankle
clonus. Muscle bulk and strength were normal, and sen-
sation was grossly intact. Coordination was inappropri-
ate for her age, and her movements were dystonic.
Investigations at 6 months showed increased urinary
excretion of MMA, peak plasma MMA levels of
4428 nmol/L (normal: 0–270 nmol/L), and plasma lac-
tate levels of 5.6 mmol/L (normal: 0.5 - 2.2 mmol/L).
These and other metabolite levels have fluctuated over
time, without intervention and independent of clinical
status. More recent measurements, taken while the child
has been well, have shown elevated plasma lactate
concentrations, with a concomitant rise in urinary
MMA and β-alanine, as well as persistently elevated
urinary aminoisobutyric acid (Figure 2). Although not
initially recognized, urine organic acid GCMS profiles
showed elevated 3-hydroxybutyric acid. Subsequent ion
extraction for m/z 191 and m/z 177 separated the peak
into 3-hydroxybutyrate and 3-hydroxyisobutyrate, isomersthat typically co-elute as a single peak, respectively. The
latter was present in concentrations approximately 10-fold
larger than the former. Additionally, methylcitrate and 3-
hydroxypropionate were absent. Urine amino acids
demonstrated increased levels of aminoisobutyrate (max-
imum 453 nmol/mol creatinine at 6 months; normal: 33–
170 nmol/mol creatinine) and β-alanine (maximum
57 mmol/mol creatinine at 29 months; normal: 0–7 mmol/
mol creatinine) (Figure 2). Plasma alanine levels have
remained within normal limits (ranging from 207 to
375 μmol/L), with a mild elevation to 646 μmol/L that
corresponded with the lactate level of 5.1 at 29 months.
Plasma ammonium, creatine kinase, liver function tests
and thyroid studies were all normal. Early acylcarnitine
profiles twice showed small elevations in C3 (maximum
0.76 μmol/L; normal: < 0.65 μmol/L) and C10 (maximum
0.36 μmol/L; normal: < 0.26 μmol/L) acylcarnitines, which
have since normalized. Quantitative plasma carnitine (free
and total), very long chain fatty acids, transferrin isoelec-
tric focusing, biotinidase, and 7-dehydrocholesterol were
all normal. Cerebrospinal fluid lactate, amino acids and
neurotransmitters were normal, as were CSF organic acids
when compared to published control values [4]. Serum
vitamin B12 and plasma homocysteine levels were normal,
and cultured fibroblasts showed normal propionate,
methyltetrahydrofolate and cyanocobalamin incorpor-
ation. While a mitochondrial respiratory chain defect was
suspected, muscle histology, immunohistochemistry and
electron microscopy were normal. Additionally, respira-
tory chain studies in frozen muscle and skin fibroblasts
were all normal.
Brain MRI at 13 and 21 months of age demonstrated a
thin corpus callosum, diffuse delay in myelination, and
very slow progression in myelination during the 8 month
interval between images (Figure 3). Note was also made
of asymmetrically enlarged lateral ventricles, with tiny
subependymal gray matter heterotopia at the wall of the
left lateral ventricle, and prominent extra-axial spaces
bifrontally. MR spectroscopy demonstrated normal NAA,
creatine, choline, and lactate peaks. Additional neuro-
logical studies have included visual evoked potentials
(mildly increased latencies, but otherwise normal), as well
as normal brainstem auditory evoked responses and nerve
conduction studies.
Molecular genetic testing included normal CGH and
SNP microarrays. Furthermore, DNA sequence analysis
found no mutations in SUCLA2 or SUCLG1, genes that
encode the succinyl-CoA ligase complex and are associ-
ated with lactic acidosis, methylmalonic aciduria and mi-
tochondrial depletion syndromes. Sequencing of SUCLG2
was not performed.
A diagnosis was not made following several months of
extensive investigations, though the collection of abnor-
mal results were highly suggestive of either a defect in
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Figure 2 Chronological outline of select investigations, with fluctuating levels over time. The variability is independent of dietary
modifications or pharmacological treatment. Normal ranges are represented by shaded areas. AIBA: 3-aminoisobutyric acid.
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tion. It was at this point that whole exome sequencing
was pursued, looking specifically for variants that could
fall within these categories.
Exome sequencing
We followed standard manufacturer protocols to per-
form target capture with the Agilent SureSelect All Exon
50 MB (V3) exome enrichment kit and sequencing of
100 bp paired end reads on Illumina HiSeq 2000, which
generated 11.7 Gb of sequence for the sample. We
removed adaptor sequences and quality trimmed reads
using the Fastx toolkit [5] and then used a custom script
to ensure that only read pairs with both mates present
were subsequently used. Reads were aligned to hg19
with BWA 0.5.9 [6], and indel realignment was done
using the GATK [7]. Duplicate reads were then marked
using Picard [8] and excluded from downstream ana-
lyses. We assessed coverage of consensus coding se-
quence (CCDS) bases using the GATK, which showed
that the sample had 92.3% of CCDS bases covered by at
least 10 reads, and 87.8% of CCDS bases covered by atleast 20 reads. Single nucleotide variants (SNVs) and
short insertions and deletions (indels) were called using
samtools mpileup [9] with the extended base alignment
quality (BAQ) adjustment (−E), and were then quality
filtered to require at least 20% of reads supporting the
variant call. Variants were annotated using both Annovar
[10] and custom scripts to identify whether they affected
protein coding sequence, and whether they had previ-
ously been seen in dbSNP132 [11], the 1000 genomes
dataset (Nov. 2011) [12], the NHLBI GO exomes [13], or
in approximately 540 exomes previously sequenced at
our center.
Variant validation
Sanger sequencing was used to validate mutations iden-
tified by next-generation sequencing and to evaluate
segregation of variants in the family. Blood samples were
obtained and DNA was extracted from the unaffected
parents and sibling. PCR was performed with primers
5′-GAAGGGCAAGTCAGTGTACC-3′ and 5′-CAACA
AACATGGAGGTTAAAATG-3′ to test for the c.514
T >C variant and 5′-GATGGCTAAGGTTTGATTGTT
Figure 3 MRI images taken at 13 and 21 months of age. (A, B) Axial FLAIR images show only minimal interval progression in myelination
over a 9 month span, with diffuse thinning of periventricular white matter evident at 13 months. (C, D) Axial T2-weighted images show markedly
delayed myelination, with mild ventricular dilatation and slight enlargement of the frontal extra-axial spaces. (E, F) Sagittal T2-weighted images
show a diffusely thin corpus callosum. MR spectroscopy demonstrated normal peaks of NAA, creatine and choline, and absence of a lactate peak.
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to test the c.1603C > T variant.
Enzyme assay
Enzyme activity measurement was performed using me-
thylmalonate semialdehyde as substrate in the presence
of NAD+ and CoenzymeA. Because methylmalonate
semialdehyde is an unstable compound, a diethyl acetal
of methylmalonate semialdehyde was synthesized as
described [14] and hydrolyzed as described [15] prior
to performing the enzymatic assay. The product of
the enzyme reaction, propionyl-CoA was converted to
propionyl-carnitine by carnitine acetyltransferase (CRAT),which was detected by tandem-mass spectrometry using
deuterium labelled propionyl-carnitine as internal stand-
ard (unpublished data, manuscript describing enzyme
assay in preparation [16]). Reference values were deter-
mined by measuring MMSDH activity in 13 different cul-
tured skin fibroblast cell lines from control subject.
Results
Whole exome sequencing identified two novel variants in
the gene ALDH6A1, supporting a diagnosis of MMSDH
deficiency. A total of 32 variants that affect protein se-
quence or canonical splice sites while fitting a recessive
disease model were identified. The only variants seen in
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mtDNA genes encoding proteins with strong support of
mitochondrial localization) [17], both occurred in
ALDH6A1. A missense mutation in exon 12 (NM_005589,
c.1603C > T), causing an arginine-to-cysteine change at
the last amino acid before the stop codon (p. Arg535Cys),
has only once been reported in the heterozygote state out
of 6503 NHLBI exomes [13], and has not been seen in the
1000 Genomes dataset [12] or the 540 exomes from other
rare disease projects studied by our sequencing facility.
A second missense mutation in exon 6 (NM_005589,
c.514 T > C), which produces a tyrosine-to-histidine
change (p. Tyr172His), has not been reported in any of
these datasets. Mutations were confirmed by Sanger
sequencing. Additionally, each parent was confirmed to be
a carrier of one of the mutations. The healthy sibling of
the patient did not carry either mutation. Both affected
amino acid residues are highly conserved among mam-
mals. The resulting amino acid changes are predicted to
be damaging by SIFT [18] (scores 0 and 0.01, respectively)
and Polyphen2 [19] (scores 0.986 and 0.838, respectively).
Further examination of the exome sequencing results
identified no rare variants in genes known to be associated
with hypomyelination, including PLP1, GJC2, AIMP1,
HSP60, FAM126A, SLC16A2, LMNB1, SLC17A5 and
L1CAM. Despite extensive investigations, no other cause
was identified for this child’s phenotype. In contrast,
exome sequencing does not make prior assumptions of
causation, and thus finding two predicted pathogenic
mutations in ALDH6A1, a gene that can be reasonably
related to the biochemical findings, is strongly suggestive
of disease causation.
Fibroblast studies at the Laboratory of Genetic Meta-
bolic Diseases (Academic Medical Center, Amsterdam,
The Netherlands) revealed reduced activity of MMSDH.
Measured activity was 36 pmol/(min.mg protein) (normal
range 51–184; mean 117; standard deviation ±33).
Discussion
MMSDH deficiency is an extremely rare, autosomal
recessive disorder of valine and thymine metabolism. To
date, mutations in ALDH6A1 have only been identified
in three individuals (summarized in Table 1). In the first
such case, the patient presented incidentally with hy-
permethioninemia on his newborn screen [1,20]. The
raised methionine could not be related to the subsequent
discovery of persistent urine and plasma abnormalities in
the form of elevated β-alanine, 3-hydroxypropionic, 3-
aminoisobutyric, 3-hydroxyisobutyric and (S)-2-(hydro-
xymethyl)butyric acids. The child has remained medically
and developmentally well as of 4 years of age. Molecular
analysis by Chambliss et al. [2] identified a homozygous
missense mutation (c.1336G >A; p. Gly446Arg) in the
ALDH6A1 gene that has 100% conservation of the glycineresidue in vertebrates, and has not been seen in the 6503
NHLBI exomes. The remaining two molecularly confirmed
cases were reported by Sass et al. [3]. One child was a
European boy born to consanguineous parents, who
presented with elevated 3-hydroxyisobutyric acid and
mild elevations in 3-hydroxypropionic and 2-ethyl-3-
hydroxypropionic acids. He had mild developmental
delay and dysmorphisms, and passed away at 26 months
of age following acute hepatoencephalopathy secondary
to liver failure. Postmortem analysis showed cerebral
edema with white matter vacuolization and microcal-
cifications in the frontal cortex, not previously seen on
imaging while alive. He was found to be homozygous for a
c.785C >A (p. Ser262Tyr) change in ALDH6A1. The sec-
ond case was a young girl of Pakistani origin, previously
described by Shield et al. [21]. She was the product of a
consanguineous union, with severe developmental delays,
dysmorphic features, microphthalmia, cataracts and post-
natal microcephaly. Brain MRI at 1 year of age showed
significantly delayed myelination, thinning of the corpus
callosum and microcephaly. Urine organic acids showed
elevated 3-hydroxyisobutyric and 3-hydroxypropionic acid
levels. Lactate levels were only mildly elevated. She was
homozygous for a c.184C > T (p. Pro62Ser) mutation in
ALDH6A1. Of note, the child’s older brother was also
found to have increased levels of 3-hydroxyisobutyric acid
without lactic acidosis, though molecular analysis was not
reported. His phenotype was on the milder end of the
spectrum, with microcephaly and moderate learning diffi-
culties. MRI of his brain showed only isolated microceph-
aly. The mutations reported in both the European and
Pakistani cases occurred in highly conserved amino acids,
and were predicted to be disease causing. The variable
clinical and biochemical spectrum demonstrated by these
three cases, in addition to the one reported here (Table 1),
illustrates the need for detailed genotype-phenotype cor-
relation studies for patients carrying ALDH6A1 mutations.
Other cases of 3-hydroxyisobutyric aciduria with meta-
bolic profiles suggestive of MMSDH deficiency have
been reported with variable clinical and biochemical
pictures [22-28]. Two of these cases had loading studies
in cultured fibroblasts that were suggestive of deficient
MMSDH enzymatic activity. The first was a male who
presented at 6 years of age with failure to thrive, vomiting,
lethargy and a metabolic acidosis [22,25]. Urine screen
showed elevated levels of 3-hydroxyisobutyric acid and
lactate. Physical examination found subtle dysmorphisms
in the form of a small, triangular face with low-set ears,
fifth finger clinodactyly, and 2/3 toe syndactyly. The
second child was a male who at 22 months of age was
found to have elevated methylmalonate and normal
propionylcarnitine levels prior to surgery for gut mal-
rotation and Meckel’s diverticulum repair [26]. He is
otherwise globally delayed, and has never had an episode
Table 1 Clinical and biochemical summary of molecularly confirmed patients in the literature
Our patientt Pollitt et al. [1] Shield et al. [21] Sass et al. [3]
Gray et al. [20] Sass et al. [3]
Chambliss et al. [2]
Patient information Female Male Female Male
Mixed European ancestry Pakistani ancestry Pakistani ancestry Mixed European ancestry
Parents non-consanguineous Consanguinity not
specified
Parents consanguineous Parents consanguineous
ALDH6A1 mutations c.514T > C c.1336G > A c.184C > T c.785C > A
c.1603C > T c.1336G > A c.184C > T c.785C > A
Biochemical
abnormalities
↑ plasma/urine MMA ↑methionine ↑ 3-hydroxypropionate
↑ lactate ↑ 3-hydroxyproprionate ↑methylcitrate Mild ↑ 3-hydroxypropionate
↑ HIBA ↑ HIBA Mild ↑ lactate ↑ HIBA
↑ AIBA ↑ AIBA ↑ HIBA ↑ β-alanine
↑ β-alanine ↑ β-alanine ↑ AIBA
CNS findings Severe developmental
delays, dystonia and microcephaly.







thin corpus callosum on MRI
No imaging reported Delayed myelination and thin
corpus callosum on MRI
No imaging reported. Frontal
cortex microcalcifications on
autopsy.
Clinical findings Tall forehead, epicanthal folds, mild
hypertelorism, short philtrum, broad















HIBA: 3-hydroxyisobutyric acid; AIBA: 3-aminoisobutyric acid.
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could not be identified in either individual [2]. Demonstra-
tion of reduced MMSDH activity in fibroblasts was not
available at the time of study.
As we have highlighted, the diagnosis of MMSDH de-
ficiency is problematic. Case reports are exceedingly rare
and the phenotype appears to be highly variable. This
raises the issue of bias of ascertainment - a common
complication of studying rare inborn errors of metabol-
ism. Adding further to the difficulty of diagnosis is that
the biochemical changes seen in our patient have been
transient and varied. Of particular note, peak plasma
MMA levels were reached when the child was approxi-
mately 6 months old, after which they progressively de-
clined to the normal range (Figure 2). This was achieved
without any intervention – dietary, pharmacologic or
otherwise. Serum MMA levels decreased from 4428 nmol/
L at 6 months to 90 nmol/L at 27.5 months. Plasma lactate
levels had a prolonged period of normalcy after 18 months
of age, with a recent increase to 6.6 mmol/L on our most
recent investigations at 34.5 months. Our investigations
failed to identify abnormalities in urine organic acids, and
showed small elevations in aminoisobutyric acid and β-
alanine in urine amino acids. One can speculate that the
abnormal findings correspond to a peak time of growthwith associated metabolite turnover. As in our case, mild
elevations in 3-hydroxyisobutyric acid, aminoisobutyric
acid and β-alanine may go unreported, or missed, due in
part to the fact that 3-hydroxyisobutyric acid is isobaric to
3-hydroxybutyric acid. Elevations in 3-hydroxybutyrate are
non-specific, and can be attributed to any process that
might induce ketogenesis. As such, 3-hydroxyisobutyrate
can be easily missed on mass spectrometry if one is not
specifically looking for that compound. We therefore sug-
gest that the finding of mild methylmalonic aciduria
should prompt a careful search for metabolites related to
MMSDH deficiency.
Previous reports of molecularly confirmed MMSDH
deficiency have described various brain abnormalities,
including postnatal microcephaly, cerebral microcal-
cifications and, in one case, acute hepatoencephalopathy
associated with cerebral edema and death. We report hy-
poplasia of the corpus callosum and profoundly delayed
myelination between 13 and 21 months of age (Figure 3).
The patient described by Shield et al. [21] similarly
showed delayed myelination at 1 year of age. It is ultim-
ately not clear how deficiency of MMSDH would cause
brain dysmyelination and developmental delays. One can
speculate on the toxicity of the semialdehyde itself, as
well as its related metabolites. It is interesting to note
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and that disorders of mitochondrial nucleotide pools are
associated with mitochondrial depletion and encephal-
opathy. For example, as is seen in our case, MMA and
lactic acidosis are also features of succinyl-CoA ligase
deficiency. Further information may be gained in the
future with the design of MMSDH knockouts in model
systems, though as of this writing there are none
available.
The place of exome sequencing in the clinic remains
unclear. In our case, it was done after an extensive diag-
nostic workup. Certainly in this patient it could have
prevented the need for a muscle biopsy. As well, it was
the only diagnostic test available for this disease, as nei-
ther enzymology nor single gene testing were available.
Furthermore, where clinical and laboratory information
is available that points to specific pathways or organelles
(such as MMA metabolism or mitochondrial disease),
this information can be used to filter the sequencing
data and increases the likelihood of finding a definitive
answer, while simultaneously reducing the number of
variants of unknown significance.Conclusions
We present the fourth molecularly confirmed case of
MMSDH deficiency, caused by compound heterozygous
mutations in the ALDH6A1 gene, and the first such case
to demonstrate a concomitant decrease in enzyme activ-
ity. This report serves to illustrate both the clinical and
biochemical variability present in this rare condition,
and highlights the importance of searching for specific
metabolites in the context of elevated MMA levels. Also
illustrated is the emerging utilization of whole exome se-
quencing coupled with predetermined variant filtering as
an early tool in the diagnosis of rare and variable condi-
tions. Finally, given the difficulties with diagnosis, we
suspect this is an under-recognized disorder, and that
our understanding of this rare condition will improve as
more patients are identified.
Abbreviations
MMSDH: Methylmalonate semialdehyde dehydrogenase; ALDH6A1: Aldehyde
dehydrogenase 6 family member A1; MMA: Methylmalonic acid; SIFT: Sorting
intolerant from tolerant; PolyPhen-2: Polymorphism phenotyping.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JLM and MTG wrote the manuscript. KMB and DB designed and coordinated
the study. MTG, DP, OYA, PC and JLM provided subspecialist consultation
services, serial clinical examinations and diagnostic testing. JS and JM carried
out the analysis of the next-generation sequencing data. AMS and KMB
arranged for Sanger sequencing of the ALDH6A1 gene. RJAW and SF carried
out biochemical testing on fibroblasts. All authors read and approved the
final manuscript.Acknowledgements
This work was funded by the Government of Canada through Genome
Canada, the Canadian Institutes of Health Research and the Ontario
Genomics Institute (OGI-049). Additional funding was provided by Genome
Quebec, Genome British Columbia, and the McLaughlin Centre. This work
was selected for study by the FORGE Canada Consortium: Finding of Rare
Disease Genes in Canada; Steering Committee: Kym Boycott (leader;
University of Ottawa), Jan Friedman (co-lead; University of British Columbia),
Jacques Michaud (co-lead; Université de Montréal), Francois Bernier
(University of Calgary), Michael Brudno (University of Toronto), Bridget
Fernandez (Memorial University), Bartha Knoppers (McGill University), Mark
Samuels (Université de Montréal), Steve Scherer (University of Toronto). We
would like to thank Janet Marcadier (Clinical Coordinator) and Chandree
Beaulieu (Project Manager) for their contribution to the infrastructure of the
FORGE Canada Consortium. The authors wish to acknowledge the
contribution of the high throughput sequencing platform of the McGill
University and Génome Québec Innovation Centre, Montréal, Canada. We
would like to thank Dr. NI Wolf, Dr MS van der Knaap, Dr. RJ Vermeulen and
Dr. MSM van Breemen of the Child Neurology Department of the VU
University Medical Center in Amsterdam for their valuable input in
interpreting the MRI images.
Author details
1Department of Genetics, Children’s Hospital of Eastern Ontario, Ottawa
ON, Canada. 2Ottawa Hospital Research Institute, Ottawa, ON, Canada.
3Department of Pediatrics, Division of Neurology, Children’s Hospital of
Eastern Ontario, University of Ottawa, Ontario, Canada. 4McGill University and
Genome Quebec Innovation Centre, Montreal, QC, Canada. 5Newborn
Screening Ontario, Children’s Hospital of Eastern Ontario, Ottawa, ON,
Canada. 6Children’s Hospital of Eastern Ontario Research Institute, University
of Ottawa, Ottawa, ON, Canada. 7Laboratory Genetic Metabolic Diseases,
Academic Medical Center, University of Amsterdam, Amsterdam, The
Netherlands. 8Department of Pediatrics, Division of Metabolics, Children’s
Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON K1H8L1,
Canada.
Received: 10 April 2013 Accepted: 21 June 2013
Published: 9 July 2013References
1. Pollitt RJ, Green A, Smith R: Excessive excretion of beta-alanine and of
3-hydroxypropionic, R- and S-3-aminoisobutyric, R- and
S-3-hydroxyisobutyric and S-2-(hydroxymethyl)butyric acids probably
due to a defect in the metabolism of the corresponding malonic
semialdehydes. J Inherit Metab Dis 1985, 8:75–79.
2. Chambliss KL, Gray RG, Rylance G, Pollitt RJ, Gibson KM: Molecular
characterization of methylmalonate semialdehyde dehydrogenase
deficiency. J Inherit Metab Dis 2000, 23:497–504.
3. Sass JO, Walter M, Shield JP, Atherton AM, Garg U, Scott D, et al:
3-hydroxyisobutyrate aciduria and mutations in the ALDH6A1 gene
coding for methylmalonate semialdehyde dehydrogenase. J Inherit Metab
Dis 2012, 35:437–442.
4. Hoffmann GF, Meier-Augenstein W, Stockler S, Surtees R, Rating D, Nyhan
WL: Physiology and pathophysiology of organic acids in cerebrospinal
fluid. J Inherit Metab Dis 1993, 16:648–669.
5. FASTX-Toolkit. http://hannonlab.cshl.edu/fastx_toolkit/.
6. Li H, Durbin R: Fast and accurate short read alignment with
burrows-wheeler transform. Bioinformatics 2009, 25:1754–1760.
7. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al:
The genome analysis toolkit: a MapReduce framework for analyzing
next-generation DNA sequencing data. Genome Res 2010, 20:1297–1303.
8. Picard-SourceForge. http://picard.sourceforge.net/.
9. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al: The
sequence alignment/map format and SAMtools. Bioinformatics 2009,
25:2078–2079.
10. Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res 2010,
38:e164.
11. dbSNP. http://www.ncbi.nlm.nih.gov/SNP.
12. 1000 genomes. http://www.1000genomes.org.
Marcadier et al. Orphanet Journal of Rare Diseases 2013, 8:98 Page 9 of 9
http://www.ojrd.com/content/8/1/9813. Exome Variant Server, NHLBI GO Exome Sequencing Project. http://evs.gs.
washington.edu/EVS/.
14. Kupiecki FP, Coon MJ: Methylmalonic semialdehyde. Biochem Prep 1960,
7:69–71.
15. Bachhawat BK, Coon MJ, Kupiecki FP, Nagle R, Robinson WG: Coenzyme a
thiol esters of isobutyric, methacrylic, and beta-hydroxyisobutyric acids
as intermediates in the enzymatic degradation of valine.
J Biol Chem 1957, 224(1):1–11.
16. Personal Communication. Manuscript in preparation.




20. Gray RG, Pollitt RJ, Webley J: Methylmalonic semialdehyde dehydrogenase
deficiency: demonstration of defective valine and beta-alanine
metabolism and reduced malonic semialdehyde dehydrogenase activity
in cultured fibroblasts. Biochem Med Metab Biol 1987, 38:121–124.
21. Shield JP, Gough R, Allen J, Newbury-Ecob R: 3-Hydroxyisobutyric aciduria:
phenotypic heterogeneity within a single family. Clin Dysmorphol 2001,
10:189–191.
22. Ko FJ, Nyhan WL, Wolff J, Barshop B, Sweetman L: 3-Hydroxyisobutyric
aciduria: an inborn error of valine metabolism. Pediatr Res 1991,
30:322–326.
23. Chitayat D, Meagher-Villemure K, Mamer OA, O’Gorman A, Hoar DI, Silver K,
et al: Brain dysgenesis and congenital intracerebral calcification
associated with 3-hydroxyisobutyric aciduria. J Pediatr 1992, 121:86–89.
24. Gibson KM, Lee CF, Bennett MJ, Holmes B, Nyhan WL: Combined malonic,
methylmalonic and ethylmalonic acid semialdehyde dehydrogenase
deficiencies: an inborn error of beta-alanine, L-valine and
L-alloisoleucine metabolism? J Inherit Metab Dis 1993, 16:563–567.
25. Boulat O, Benador N, Girardin E, Bachmann C: 3-hydroxyisobutyric aciduria
with a mild clinical course. J Inherit Metab Dis 1995, 18:204–206.
26. Roe CR, Struys E, Kok RM, Roe DS, Harris RA, Jakobs C: Methylmalonic
semialdehyde dehydrogenase deficiency: psychomotor delay and
methylmalonic aciduria without metabolic decompensation.
Mol Genet Metab 1998, 65:35–43.
27. Sasaki M, Kimura M, Sugai K, Hashimoto T, Yamaguchi S:
3-hydroxyisobutyric aciduria in two brothers. Pediatr Neurol 1998,
18:253–255.
28. Sasaki M, Iwata H, Sugai K, Fukumizu M, Kimura M, Yamaguchi S: A severely
brain-damaged case of 3-hydroxyisobutyric aciduria. Brain Dev 2001,
23:243–245.
doi:10.1186/1750-1172-8-98
Cite this article as: Marcadier et al.: Mutations in ALDH6A1 encoding
methylmalonate semialdehyde dehydrogenase are associated with
dysmyelination and transient methylmalonic aciduria. Orphanet Journal
of Rare Diseases 2013 8:98.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
